PreCoDe
PreCoDe is a proof-of-concept trial to investigate the efficacy of prasinezumab to slow or prevent cognitive decline in people with Parkinson's disease carrying a severe mutation in the GBA (glucocerebrosidase) genePrevent Cognitive Decline in GBA-associated Parkinson's Disease (PreCoDe)
This is a proof-of-concept trial to investigate the efficacy of prasinezumab to slow or prevent cognitive decline in people with Parkinson's disease carrying a severe mutation in the GBA (glucocerebrosidase) gene. The duration of the intervention per patient will be 104 weeks with monthly infusions. The investigators plan to enroll 120 participants (60 participants per treatment arm). This study will be conducted across Europe in the following countries: France, Germany, Italy, Luxembourg, Spain, Sweden, UK.
The primary objective of the study is to assess if the group treated with Prasinezumab declines less in cognitive function measured by the Parkinson Disease Cognitive Composite Score (PDCCS) as compared to the Placebo group.
Population: 35 Years to 80 Years (Adult, Older Adult) | Study type: Interventional, Clinical Trial under the EU Clinical Trials Regulation
Drug: Prasinezumab | Funding information: Michael J. Fox Foundation for Parkinson’s Research